Tim Meyer

机构：University College Hospital, Royal Free London NHS Foundation Trust, The Royal Free Hospital, Cancer Research UK, University College London · ORCID：0009-0008-7942-6448

发表论文 17 篇 · 总被引 418 次 · h-index 6

代表论文

• Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2025 · Annals of Oncology · 被引 237)
• A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). (2020 · Journal of Clinical Oncology · 被引 75)
• A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results (2019 · Annals of Oncology · 被引 69)
• Malignant Somatostatinoma Presenting with Diabetic Ketoacidosis and Inhibitory Syndrome: Pathophysiologic Considerations (2010 · Endocrine Practice · 被引 9)
• LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma. (2025 · Journal of Clinical Oncology · 被引 7)
• Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma (2025 · ESMO Open · 被引 6)